glp 1 drug shortage FDA Ends Compounding of GLP-1 Drugs as Shortages Improve, The U.S. Food and Administration (FDA) has announced the end of the for GLP-1 weight loss drugs like Ozempic, leading to the Ozempic's patent problem: how Novo

Dr Nick Yim, as a GP, are you getting a lot of requests for Ozempic or Ozempic-style drugs to be written out for prescriptions for your patients

Semaglutide reduces A1c by 1.0 to 1.5 percentage points on average

Some people who struggle with tirzepatide do fine on semaglutide

Thus, all patients were followed from study cohort entry until one of the study outcomes (described below), treatment discontinuation, initiation of a study drug in the comparator group, death from any cause (depending on the outcome), end of registration, or the end of the study period (29 March 2021), whichever came first

CagriSema (a combination of semaglutide and cagrilintide) is expected to seek regulatory approval in late 2025, and market overviews expect 1-2 new drugs entering the market every year for the next couple of years